Barclays
ELEV

Barclays’s Elevation Oncology ELEV Stock Holding History

Barclays’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,538
Closed -$15.4K – 5346
2025
Q1 		$15.4K Sell
59,538
-28,070
-32% -$16K ﹤0.01% 4818
2024
Q4 		$49.3K Buy
87,608
+15,531
+22% +$9.17K ﹤0.01% 4765
2024
Q3 		$43.2K Buy
72,077
+54,167
+302% +$80.3K ﹤0.01% 4784
2024
Q2 		$48.4K Buy
+17,910
New +$67.4K ﹤0.01% 4225
2023
Q4 		– Sell
-18,350
Closed -$12.2K – 5247
2023
Q3 		$12.2K Buy
+18,350
New +$18.6K ﹤0.01% 4273
2023
Q1 		– Sell
-392
Closed -$372 – 5159
2022
Q4 		$372 Hold
392
– – ﹤0.01% 5162
2022
Q3 		$0 Hold
392
– – ﹤0.01% 4884
2022
Q2 		$1K Hold
392
– – ﹤0.01% 4931
2022
Q1 		$1K Buy
+392
New +$1.57K ﹤0.01% 4827

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Barclays's ELEV Position: Q2 2025 in Review

Barclays sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 59,538 shares — an estimated $15.4K sold.

Barclays first reported a position in ELEV in Q1 2022 and held it in 9 quarters. The position peaked at $49.3K in Q4 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Barclays reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 59,538 Elevation Oncology shares in Q2 2025, an estimated $15.4K.
  • Barclays first reported a position in Elevation Oncology in Q1 2022 and held it in 9 quarters.
  • Barclays's Elevation Oncology position peaked at $49.3K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.